Solid Tumors

We are developing degraders of cyclin-dependent kinase 2 (CDK2), cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6), important targets for a range of cancers including 30% of breast and esophageal cancers, 50% of pancreatic and 40% of bladder cancers. CDK4 and CDK6 are clinically validated targets in the context of breast cancers. In preclinical breast cancer models, our lead candidates potently degrade CDK4 and CDK6 resulting in robust inhibition of phosphorylated Rb and cell cycle arrest.